Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Sep;92(9):1511-1517.
doi: 10.1002/jmv.26035. Epub 2020 Jun 2.

Increase in COVID-19 cases and case-fatality and case-recovery rates in Europe: A cross-temporal meta-analysis

Affiliations
Review

Increase in COVID-19 cases and case-fatality and case-recovery rates in Europe: A cross-temporal meta-analysis

Engin Karadag. J Med Virol. 2020 Sep.

Abstract

The new coronavirus (COVID-19) infection reported in China in December 2019 has become a pandemic in a few weeks, affecting the entire world. In this respect, it is crucial to determine the case-increase, case-fatality, and case-recovery rates to control COVID-19. In this study, the case-increase, case-fatality, and case-recovery rates of COVID-19 in 36 European countries were analyzed with the meta-analysis method using data released by the health organizations and WHO. The data were obtained from the website of health organizations of 36 European countries and the website of WHO until 11 May 2020. The analyses were carried out on 1 744 704 COVID-19-diagnosed cases in 36 European countries. The case-increase, case-fatality and case-recovery rates of COVID-19 were calculated using 95% confidence intervals (95% CI), single-arm meta-analysis, cross-temporal meta-analysis, and meta-regression random-effects model. The standardized case-increase rate of COVID-19 is 5% (95% CI [0.040, 0.063]) and the average case-increase rate in European countries has started to decline by around 3% (95% CI [0.047, 0.083]) weekly. The countries with the highest rate of case increase are Belgium, Sweden, Russia, the Netherlands and the United Kingdom. Although the case-fatality rate of COVID-19 patients was 4.5% as of May 11 (95% CI [0.037-0.055]), this rate is 6.3% (95% CI [0.047, 0.083]) in standardized time (6th week). The case-recovery rates of patients are 46% (95% CI [0.376-0.547]). This study presents important results regarding the COVID-19 pandemic in Europe. Although the rate of increase in new COVID-19 cases has dropped, there is not much decline in the case-fatality rates and no increase in case-recovery rates. The case-fatality rate of COVID-19 in Europe was estimated to be in the range of 4% to 4.5% and a minimum of 4 weeks (as of 11 May) is expected to have the figure below 1% in a country with an average case-increase rate. Monitoring case fatalities in Belgium, the Netherlands and Sweden, and treatment successes in Germany and Austria play a role of utmost importance.

Keywords: COVID-19; Europe; case-fatality rate; case-increase rate; case-recovery rate.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Preferred Reporting Items for Systematic Reviews and Meta‐Analyses flow diagram

Similar articles

Cited by

References

    1. Yuan J, Li M, Lu ZK. Monitoring transmissibility and mortality of COVID‐19 in Europe. Int J Infect Dis. 2020;95:311‐315. 10.1016/j.ijid.2020.03.050 - DOI - PMC - PubMed
    1. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497‐506. 10.1016/S0140-6736(20)30183-5 - DOI - PMC - PubMed
    1. Livingston E, Bucher K. Coronavirus disease 2019 (COVID‐19) in Italy. JAMA. 2020;323(14):1335. 10.1001/jama.2020.4344 - DOI - PubMed
    1. Onder G, Rezza G, Brusaferro S. Case‐Fatality Rate and Characteristics of Patients Dying in Relation to COVID‐19 in Italy. JAMA. 2020;323(18):1775–1776. 10.1001/jama.2020.4683 - DOI - PubMed
    1. Wallinga J, Teunis P. Different epidemic curves for severe acute respiratory syndrome reveal similar impacts of control measures. Am J Epidemiol. 2004;160:509‐516. 10.1093/aje/kwh255 - DOI - PMC - PubMed